Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement
1 other identifier
observational
300
1 country
18
Brief Summary
The purpose of the study is to procure blood samples from patients who present to the Emergency Department with suspected ACS (Acute Coronary Syndrome).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2006
18 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2006
CompletedFirst Submitted
Initial submission to the registry
December 21, 2006
CompletedFirst Posted
Study publicly available on registry
December 25, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2008
CompletedDecember 18, 2009
December 1, 2009
December 21, 2006
December 17, 2009
Conditions
Keywords
Interventions
Eligibility Criteria
Patients presenting the to the ED within 6 hours with symptoms consistent with ACS.
You may qualify if:
- Age 18 years or older at time of enrollment
- Patient presenting to the ED within 6 hours or less from symptom (chest discomfort consistent with possible ACS) onset
- Patient experiencing at least 30 minutes of chest discomfort, consistent with possible ACS, from time of symptom onset; patients who have symptoms of shorter duration due to pharmacologic intervention may be included
- Physician plans to perform objective cardiac testing as defined by the protocol
You may not qualify if:
- Patient (or legal representative) unable or unwilling to provide informed consent
- Patient (or legal representative) refusal of medical record review or telephone follow-up at 30 days or 6 months
- Patient (or legal representative) refusal of multiple blood sample collection over the study period
- Prisoners or other institutionalized individuals
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (18)
UC Davis
Sacramento, California, United States
Yale University
New Haven, Connecticut, United States
St Agnes Hospital
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Spectrum Health Hospitals
Grand Rapids, Michigan, United States
Ingham Regional Medical Center
Lansing, Michigan, United States
New York Methodist Hosptial
Brooklyn, New York, United States
SUNY Stony Brook
Stony Brook, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Ohio State University Medical Center
Columbus, Ohio, United States
University of Virginia
Charlottesville, Virginia, United States
Sentara Norfolk General Hopsital
Norfolk, Virginia, United States
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States
Biospecimen
Plasma Specimens
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Frank Peacock, MD
The Cleveland Clinic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 21, 2006
First Posted
December 25, 2006
Study Start
December 1, 2006
Study Completion
June 1, 2008
Last Updated
December 18, 2009
Record last verified: 2009-12